API Holdings Limited (PharmEasy)
PharmEasy Unlisted Shares (API Holdings) — After the Crash, a Real Turnaround Attempt
PharmEasy is the unlisted market’s most famous fall — a $5.6 billion valuation cut by ~90% in a brutal debt reckoning. But FY26 delivered something the bears didn’t expect: the company’s first-ever positive EBITDA. Here’s the full arc — crash, surgery, and what you’re actually buying at today’s price.
| PharmEasy (API Holdings) Unlisted Share | Details |
| Our Buy Price | ₹4.50 per share |
| Our Sell Price | ₹5.25 per share |
| Lot Size | 1000 shares (min. investment ≈ ₹5250) |
| ISIN | INE0DJ201029 |
| Founded | 2015 (group), Mumbai |
| MD & CEO | Rahul Guha (also MD & CEO, Thyrocare) |
| Key backers | Ranjan Pai (MEMG/Claypond), Prosus, Temasek, 360 ONE |
[Get Live PharmEasy Quote on WhatsApp] [Sell Your PharmEasy Shares]
About API Holdings
API Holdings is the parent of India’s best-known digital healthcare brands: PharmEasy (consumer e-pharmacy and teleconsultation), Thyrocare (the listed diagnostics chain it majority-owns), plus B2B pharma distribution arms Ascent and Aknamed. Three engines — B2B distribution, B2C delivery, diagnostics — make it India’s largest integrated digital healthcare platform by reach.
The Crash — Told Straight
At the 2021 peak, API Holdings was valued at $5.6 billion and paying for acquisitions (including Thyrocare) with expensive debt. When rates rose and the IPO window shut, the company breached covenants on its Goldman Sachs facility (which had refinanced a ₹2,200 crore Kotak loan), forcing a deeply discounted rights issue in 2024 at roughly $710 million — a ~90% valuation haircut (some investor marks went lower still). A ₹3,500 crore recapitalisation led by Ranjan Pai’s MEMG reset the balance sheet; the co-founders exited executive roles through 2025; and Thyrocare’s Rahul Guha took over as group MD & CEO. Monthly cash burn reportedly fell from ~₹50 crore to under ₹2 crore.
The Turnaround — Now in the Numbers
| Particulars (Consolidated) | FY24 | FY25 | FY26 |
| Revenue from Operations | ₹5,664 Cr | ₹5,872 Cr (+3.7%) | ₹6,869 Cr (+14.3%) |
| Adjusted EBITDA | ₹(515) Cr | ₹(231) Cr | +₹62.5 Cr — first positive year |
| Net Loss | ₹(2,534) Cr | ₹(1,572) Cr (−38%) | narrowing further |
| Finance Cost | — | ₹506 Cr | ₹394.7 Cr |
What the numbers say: FY25 was the stabilisation year — flat revenue, losses cut 38% as finance costs fell post-recap. FY26 was the inflection: revenue growth returned at 14.3%, gross margin expanded to 19.8%, operating expenses actually declined, and group adjusted EBITDA turned positive for the first time in the company’s history. Inside the mix, Thyrocare keeps compounding (FY25: revenue ₹687 crore, PAT ₹90.8 crore, both up ~20–30%), and the consumer PharmEasy app halved its EBITDA losses with Q4 FY26 approaching breakeven. The milestone that decides the re-IPO story: full-year B2C breakeven in FY27.
Why Investors Buy PharmEasy Unlisted Shares
- Post-crash entry — today’s price already reflects the ~90% reset; you’re buying the turnaround, not the hype.
- First positive EBITDA with professional (non-founder) management and disciplined capital allocation.
- Thyrocare inside — a profitable, listed diagnostics asset provides a hard-value anchor within the group.
- Tiny ticket size — at a ₹5250 minimum, it’s the most accessible turnaround bet in the unlisted market.
- Serious backers stayed — MEMG, Prosus, Temasek and 360 ONE participated in the reset rather than walking away.
Key Risks
- Still loss-making at the net level — positive EBITDA is a milestone, not profitability; interest and depreciation still bite.
- Thin margins in e-pharmacy — a fiercely competitive category (Tata 1mg, Apollo 24|7, quick-commerce entrants) with ~1% group EBITDA margin.
- Regulatory overhang — online medicine rules, diagnostics pricing scrutiny and healthcare-sector intervention risk remain live.
- Dilution history — past rescues came at savage discounts; another stumble could repeat that pattern.
- No confirmed IPO — the “re-IPO” is a narrative contingent on FY27 execution, not a filing.
How to Buy or Sell
Live quote → deal confirmation → KYC → off-market demat transfer, prompt settlement: buy unlisted shares. Holding API Holdings from ESOPs or the 2021-era rounds and want to exit or average? Sell unlisted shares — we quote both ways, honestly, at every stage of a turnaround.
FAQs — PharmEasy Unlisted Shares
What is the PharmEasy unlisted share price today?
We are buying at ₹4.50 and selling at ₹5.25 per share (lot of 1000 — about ₹5250 minimum). WhatsApp us for a live quote.
Why is the PharmEasy share price so low?
A ~90% valuation reset — from $5.6 billion at peak to roughly $710 million in the 2024 recapitalisation — after a debt crisis forced a deeply discounted rights issue. The low per-share price reflects that reset plus a very large share count.
Is PharmEasy profitable now?
Not yet at the net level, but FY26 marked its first-ever positive adjusted EBITDA (₹62.5 crore) on revenue of ₹6,869 crore, up 14.3% — a genuine operational inflection after years of heavy losses.
Will PharmEasy IPO again?
No filing exists. The re-IPO narrative depends on the consumer business reaching full-year EBITDA breakeven, targeted for FY27. Treat all listing talk as speculation until a DRHP appears.
Related unlisted shares: OYO (PRISM) • InCred Holdings • Care Health Insurance • Pharmed Limited • Lakeshore Hospital
